http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2672874-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efda4e98a9caff2d8315f180c7c74d5b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 |
| filingDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de757ed72c58b09e4674dec006bc50c2 |
| publicationDate | 2018-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2672874-C2 |
| titleOfInvention | Methods and systems for identifying and treating anti-progestin sensitive tumours |
| abstract | FIELD: medicine. n SUBSTANCE: group of inventions relates to medicine and can be used to suppress the growth of a tumour susceptible to growth inhibition by anti-progestins. To do this end, a sample of the patient's tissue, which presumably is oncogenic or cancerous, is obtained. Progesterone receptor-positive (PR-positive) cells are detected in the tissue sample. Degree of spread of progesterone receptor foci in the nuclei of progesterone-positive cells present in said tissue sample is determined. Onapristone antiprogestin is administered to the patient if there are clearly expressed progesterone receptor foci in said tissue sample that exceed 5 % of the number of PR-positive cells. Methods are also disclosed for treating a patient with a tumour susceptible to growth inhibition by anti-progestins, or who presumably has a tumour susceptible to growth inhibition by onapristone, and a system for classifying the tumour as susceptible to onapristone treatment. n EFFECT: group of inventions provides treatment of a patient with a tumour susceptible to growth inhibition by onapristone. n 17 cl, 11 tbl, 4 dwg, 6 dwg |
| priorityDate | 2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.